close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

2.250 -0.080 (-3.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
Via ACCESS Newswire
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
Via ACCESS Newswire
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
Via ACCESS Newswire
Ensysce Biosciences Narrows Loss in Q2
Via The Motley Fool
Topics Intellectual Property
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
Via ACCESS Newswire
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Via ACCESS Newswire
These stocks that are showing activity before the opening bell on Wednesday.
Before the opening bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Via ACCESS Newswire
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Via ACCESS Newswire
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
Via ACCESS Newswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Ensysce Biosciences Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Via ACCESS Newswire
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why ServiceNow Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Top movers in Wednesday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why
Ensysce Biosciences rises after patent notice for PF9001, a methadone prodrug aimed at safer opioid use with overdose protection technology. 
Via Benzinga
Topics Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Via ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Crude Oil Falls Over 3%; Philip Morris Earnings Top Views
 
Via Benzinga
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Via ACCESS Newswire
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled
The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed. 
Via Stocktwits
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today